Botulinum Toxin Injection Market Growth, Size, Share, Industry Report and Forecast 2021-2027

The global botulinum toxin injection market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Botox or botulinum toxin is a drug made from a toxin that is produced by the bacterium clostridium botulinum and is used in small doses for the treatment of health problems such as temporary smoothing of facial wrinkles and improving appearance. The major factor for the growth of the market during the forecast period is the increasing demand for cosmetic non-invasive surgical procedures.

Moreover, the market is growing due to new product launches. For instance, in July 2021, Allergan, an AbbVie company announced the approval of a label expansion of BOTOX by the US Food and Drug Administration (FDA) to include eight new muscles for the treatment of upper limb spasticity in adults. Furthermore, the ongoing R&D is further expected to boost the growth of the market. For instance, as per UC SanDiego Health, researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego, in collaboration with two physicians from Germany with help of the US FDA’s Adverse Effect Reporting System (FAERS) database found that the Botox Injections may reduce anxiety in 2021, which in turn is driving the growth of the market.

To Request a Sample of our Report on Botulinum Toxin Injection Market: https://www.omrglobal.com/request-sample/botulinum-toxin-injection-market

Some major players in the market include Ipsen Pharma, Revance Therapeutics Inc., and AbbVie Inc. (Allergan plc), among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2020, Ajinomoto Bio-Pharma Services and Revance Therapeutics announced a strategic commercial manufacturing agreement. The agreement was aimed at the supply of DaxibotulinumtoxinA for Injection.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered-

· By Application

· By Type

· By End-User

• Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

• Competitive Landscape- Ipsen Pharma, Revance Therapeutics Inc., and AbbVie Inc. (Allergan plc), among others.

(Get 15% Discount on Buying this Report)

A full Report of Botulinum Toxin Injection Market is Available @ https://www.omrglobal.com/industry-reports/botulinum-toxin-injection-market

Global Botulinum Toxin Injection Market Report Segment

By Application

• Therapeutics

o Chronic Migraine

o Spasticity

o Overactive Bladder

o Cervical Dystonia

o Blepharospasm

o Others

• Aesthetics

By Type

• Botulinum Toxin Type A

• Botulinum Toxin Type B

By End-User

• Specialty & Dermatology Clinics

• Hospitals & Clinics

• Others

Global Botulinum Toxin Injection Market Report Segment by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.